EUTHYROX

LOE Approaching

levothyroxine sodium

NDAORALTABLET
Approved
May 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4

Mechanism of Action

synthesis. Triiodothyronine (T3) and L-thyroxine (T4) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins. The physiological actions of thyroid…

Indications (5)

hypothyroidism during the recovery phase of subacute thyroiditissecondary (pituitary)tertiary (hypothalamic) congenitalacquired hypothyroidismradioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer

Clinical Trials (4)

NCT05174000Phase 1Completed

BE of Euthyrox® Tablets (Merck Nantong Versus Merck Darmstadt Sites)

Started Jan 2022
56 enrolled
Healthy
NCT04037748Phase 1Completed

Bioequivalence of Two Formulations of Levothyroxine Sodium 200 Micrograms (mcg) Under Tablet Form

Started Jun 2019
72 enrolled
Healthy
NCT03094416Phase 4Completed

Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors

Started Jul 2018
66 enrolled
Hypothyroidism;Postablative
NCT01916304Phase 2Completed

Study of Dose Adjustment From Levothyroxine to a New Levothyroxine Sodium Test Formulation

Started Jul 2013
101 enrolled
Hypothyroidism
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers